
The TRANSFORM-HF Trial aimed to compare the effectiveness of torsemide versus furosemide in patients hospitalized with heart failure. The primary outcome was all-cause mortality assessed in a time-to-event analysis. Following a routine DSMB meeting in February 2022, recruitment was stopped because the sample size was sufficient to answer the primary research question with statistical validity. The primary results will be presented at the AHA 2022 Scientific Session. The trial is expected to provide evidence regarding whether torsemide improves clinical and patient-reported outcomes compared with furosemide.
Like
Save
Share